Urosepsis

Urosepsis is sepsis originating from a urogenital tract infection, accounting for 9–31% of all sepsis cases, with a mortality of 20–40%. [1] Approximately 80% of cases are due to obstructive uropathy, with ureterolithiasis being the most common cause. [1-2] The following is a comprehensive clinical summary organized for emergency medicine and primary care workflows.

1. History

• Key HPI questions: Onset and duration of urinary symptoms (dysuria, frequency, urgency, hematuria), flank/back pain, fever/chills/rigors, nausea/vomiting, prior UTIs or urologic procedures
• Symptom characterization: Fever is often high-grade with rigors; flank pain localizes to the upper tract; lower urinary symptoms may or may not be present [3]
• Timing/triggers: Recent urologic instrumentation (cystoscopy, stent placement, PCNL), recent catheterization, recent hospitalization or antibiotic use [2-3]
• Severity/progression: Rapid deterioration from seemingly innocuous UTI symptoms to septic shock can occur within hours [4]
• Associated symptoms: Confusion/altered mental status, oliguria, dyspnea, abdominal pain
• Important negatives: Absence of flank pain does not exclude upper tract source; elderly and immunocompromised patients may present without fever [5]

2. Alarm Features

• Hemodynamic instability: SBP ≤100 mmHg, MAP <65 mmHg, tachycardia
• Altered mental status (GCS <15) [4]
• Respiratory distress: RR ≥22, SpO2 <94%
• Lactate ≥2 mmol/L — defines septic shock when combined with vasopressor requirement [4][6]
• Oliguria/anuria — suggests obstructive uropathy or AKI
• Rigors with high fever (>39°C) or hypothermia (<36°C)
• Signs of DIC: petechiae, oozing from IV sites, thrombocytopenia [7]
• Pyonephrosis or emphysematous pyelonephritis on imaging — surgical emergency [3]

3. Medications

Empiric IV antibiotics (administer within 1 hour for septic shock, within 3 hours for sepsis without shock): [6]

• First-line empiric options (per IDSA 2025 cUTI guidelines): IV ceftriaxone, piperacillin-tazobactam, or a fluoroquinolone, guided by a 4-step approach: (1) severity of illness, (2) risk factors for resistance, (3) patient-specific considerations, (4) local antibiogram [8]
• If ESBL risk or critically ill: Carbapenems (meropenem 1g IV q8h, ertapenem 1g IV q24h) are preferred [9-10]
• If Enterococcus suspected (indwelling catheter, prior cultures): Add ampicillin or vancomycin
• Avoid: Nitrofurantoin and oral fosfomycin (inadequate tissue/serum levels for systemic infection) [3]
• De-escalate once culture and susceptibility data are available; transition to oral therapy when clinically improving, able to tolerate PO, and an effective oral option exists [11]

Medications that increase UTI/urosepsis risk: Immunosuppressants, chronic corticosteroids, anticholinergics (urinary retention)

4. Diet

• Acute phase: NPO if hemodynamically unstable or if urologic intervention anticipated
• Hydration: Aggressive IV fluid resuscitation is the priority; oral hydration once stabilized
• Long-term: Adequate fluid intake (≥2L/day) to reduce recurrent UTI/stone risk; dietary modifications based on stone composition if urolithiasis is the underlying cause

5. Review of Systems

• GU: Dysuria, frequency, urgency, hematuria, flank pain, suprapubic pain, urinary retention, penile/vaginal discharge
• Constitutional: Fever, chills, rigors, malaise, night sweats
• GI: Nausea, vomiting, diarrhea, abdominal pain (may mimic intra-abdominal pathology)
• Neurologic: Confusion, lethargy, delirium (especially elderly)
• Respiratory: Dyspnea, tachypnea (may indicate ARDS or metabolic acidosis compensation)
• Skin: Mottling, delayed capillary refill, petechiae

6. Collateral History and Family History

• Collateral: Prior urine culture results and susceptibilities (critical for guiding empiric therapy), recent antibiotic use, recent urologic procedures, baseline mental status, functional status, indwelling devices (Foley, nephrostomy, ureteral stent) [8]
• Family history: Generally not a major factor; however, family history of urolithiasis or polycystic kidney disease may be relevant
• Social context: Nursing home residence (higher MDR risk), ability to comply with outpatient follow-up

7. Risk Factors

• Obstructive uropathy (urolithiasis, BPH, strictures, tumors) — present in ~80% of cases [1-2]
• Urinary catheterization (indwelling or intermittent) [12]
• Diabetes mellitus — 43% higher culture-positive rate [12-13]
• Immunosuppression (transplant, chemotherapy, HIV)
• Chronic kidney disease [12]
• Female sex (higher culture-positive rate in stone-associated urosepsis) [13]
• Advanced age (>65 years) [12]
• Recent urologic instrumentation (cystoscopy, PCNL, TURP, stent exchange) [2]
• Prior antibiotic exposure and healthcare contact (increased MDR risk) [5]
• Structural urinary tract abnormalities (neurogenic bladder, vesicoureteral reflux)

8. Differential Diagnosis

• Pyelonephritis without sepsis — fever + flank pain + pyuria but no organ dysfunction
• Nephrolithiasis (uncomplicated) — colicky flank pain, hematuria, no systemic toxicity
• Intra-abdominal pathology: Acute cholecystitis, appendicitis, diverticulitis, ruptured AAA [3]
• Pelvic inflammatory disease (in women)
• Prostatitis/prostatic abscess (in men) [14]
• Renal abscess or perinephric abscess
• Emphysematous pyelonephritis — a surgical emergency; gas on imaging
• Sepsis from another source with incidental bacteriuria (especially in elderly with asymptomatic bacteriuria)
• Renal vein thrombosis

9. Past Medical History

• Prior UTIs, pyelonephritis, or urosepsis episodes
• History of urolithiasis, BPH, urologic surgery
• Diabetes, CKD, immunosuppression
• Indwelling urinary devices (current or recent)
• Prior urine culture organisms and susceptibilities — the single most useful piece of data for guiding empiric therapy [8]
• Antibiotic allergies (especially beta-lactam, fluoroquinolone)

10. Physical Exam

• Vitals: Temperature (fever >38°C or hypothermia <36°C), HR (tachycardia >90), RR (tachypnea ≥22), BP (hypotension SBP ≤100), SpO2
• General: Toxic appearance, rigors, diaphoresis, altered mental status
• Abdomen: Suprapubic tenderness, distended bladder (retention)
• Flank: CVA tenderness — hallmark of upper tract involvement [3][15]
• GU: Examine for phimosis, urethral discharge, scrotal pathology (epididymitis/orchitis), vaginal discharge
• Rectal (men): Prostate tenderness/boggy prostate (prostatitis/abscess)
• Skin: Mottling, petechiae, delayed capillary refill (>3 seconds), check catheter sites
• Extremities: Peripheral perfusion, edema

11. Lab Studies

• CBC with differential: Leukocytosis (>12,000) or leukopenia (<4,000), bandemia, thrombocytopenia [5]
• BMP/CMP: Creatinine (AKI), BUN, electrolytes (hyperkalemia in AKI), glucose (hyperglycemia common in sepsis)
• Lactate: ≥2 mmol/L associated with tissue hypoperfusion; serial lactate to guide resuscitation [6]
• Procalcitonin: Elevated in bacterial sepsis; useful for risk stratification (≥0.5 ng/mL suggests systemic infection) [16-17]
• CRP: Elevated; nonspecific but useful for trending
• Coagulation studies: PT/INR, fibrinogen, D-dimer (DIC screening) [16]
• LFTs: Elevated aminotransferases in sepsis-related organ dysfunction [7]
• Blood cultures: 2 sets (aerobic + anaerobic) from separate sites before antibiotics [18]
• Urinalysis + urine culture: Pyuria, bacteriuria, nitrites; culture for organism identification and susceptibilities [18-19]
• Blood gas (VBG/ABG): Metabolic acidosis, lactate

12. Imaging

• First-line: Renal/bladder ultrasound — rapid, bedside, identifies hydronephrosis, pyonephrosis, bladder distension, renal abscess [1][14]
• Gold standard: CT abdomen/pelvis with contrast — indicated for sepsis, suspected obstruction, abscess, emphysematous pyelonephritis, or failure to improve [3][18]
• When imaging is unnecessary: Uncomplicated pyelonephritis in a young, otherwise healthy patient responding to antibiotics [3]
• CT KUB (non-contrast): Adequate for stone detection but misses abscess and soft tissue detail

13. Special Tests

Scoring systems:

• SOFA score (≥2 points = sepsis) — the standard for defining sepsis per Sepsis-3 [4][8]
• qSOFA (≥2 of: altered mentation, SBP ≤100, RR ≥22) — screening tool, but the Surviving Sepsis Campaign 2026 guidelines recommend NEWS, NEWS2, MEWS, or SIRS over qSOFA as a single screening tool [20]
• Point-of-care ultrasound (POCUS): Assess for hydronephrosis, IVC collapsibility (volume status), cardiac function
• Bladder scan: Post-void residual to assess for urinary retention
• Urine Gram stain: Rapid identification of gram-negative vs. gram-positive organisms to guide initial therapy

14. ECG

• Indications: All septic patients, especially those with tachycardia, hypotension, chest pain, or elderly patients
• Common findings in sepsis:
  • Sinus tachycardia (39% of sepsis patients) [21]
  • QT prolongation (54% of sepsis patients) — associated with poor outcomes [21]
  • Atrial fibrillation/flutter (8.8%) — new-onset AF associated with 2.2× higher odds of poor outcomes [21]
  • ST changes — may mimic ACS; sepsis-related myocardial dysfunction can cause ST elevation with reciprocal changes even without coronary occlusion [22]
  • Decreased QRS amplitude in septic shock [23]
• Electrolyte-related changes: Hyperkalemia (peaked T waves, widened QRS) in AKI; hypokalemia (U waves, ST depression) from fluid resuscitation [24-25]

15. Assessment

Severity stratification (per Sepsis-3 definitions): [4-5]

• Sepsis: Suspected UTI + SOFA ≥2 (life-threatening organ dysfunction)
• Septic shock: Sepsis + vasopressor requirement to maintain MAP ≥65 mmHg + lactate >2 mmol/L despite adequate fluid resuscitation

Typical presentation: Elderly patient with obstructive uropathy (stone, BPH) presenting with fever, rigors, flank pain, and hemodynamic instability. E. coli is the causative organism in ~50–65% of cases. [4][13]

Atypical presentations: Elderly or immunocompromised patients may present with confusion, hypothermia, or nonspecific decline without localizing urinary symptoms. [5]

Complications: AKI, ARDS, DIC, septic shock, multi-organ failure, septic cardiomyopathy, critical illness polyneuropathy. [7]

16. Treatment Plan

Initial stabilization (Hour-1 Bundle):

• IV access (2 large-bore IVs), continuous monitoring
• Fluid resuscitation: Balanced crystalloid (LR preferred), 500–2,000 mL (up to ~30 mL/kg) for hypotension/hypoperfusion; reassess frequently with dynamic measures [6][18]
• Blood cultures × 2 sets + urine culture before antibiotics [18]
• Lactate measurement [6]
• Empiric IV antibiotics within 1 hour if septic shock, within 3 hours if sepsis without shock [6]

Antibiotic selection (IDSA 2025 four-step approach): [8]

• Non-septic, low risk for resistance: Ceftriaxone 2g IV q24h or fluoroquinolone
• Septic, no MDR risk factors: Piperacillin-tazobactam 4.5g IV q6h or cefepime 2g IV q8h
• Septic with MDR risk factors (prior ESBL, recent antibiotics, healthcare exposure): Meropenem 1g IV q8h [9-10]
• Enterococcal coverage if indicated: Add ampicillin 2g IV q4h or vancomycin

Vasopressors:

• Norepinephrine is first-line if hypotension persists after initial fluid resuscitation; target MAP ≥65 mmHg [6][18]
• May be started via peripheral IV or IO without central access [18]

Source control — CRITICAL in urosepsis: [5][26-27]

• Obstructing stone with infection: Urgent decompression via percutaneous nephrostomy (PCN) or retrograde ureteral stent (RUS) — both are effective; choice depends on clinical scenario and available expertise [26][28-29]
  • PCN may be preferred in pyonephrosis or when larger drainage is needed [28][30]
  • Definitive stone treatment should be deferred until sepsis resolves [26]
• Infected indwelling catheter: Remove and replace if needed [18]
• Abscess: Percutaneous or surgical drainage

IV-to-oral transition: Once clinically improving, tolerating PO, and an effective oral option is available (fluoroquinolone, TMP-SMX, or oral cephalosporin based on susceptibilities) [11]

Duration: Typically 7–14 days depending on source control and clinical response; shorter courses (7 days) are increasingly favored when source control is adequate [5]

17. Disposition

Admission criteria (most urosepsis patients require admission):

• Sepsis or septic shock (ICU admission within 6 hours if ICU-level care needed) [6][20]
• Hemodynamic instability or vasopressor requirement → ICU
• Obstructive uropathy requiring urgent intervention
• Inability to tolerate oral medications (persistent vomiting)
• Significant comorbidities (CKD, immunosuppression, diabetes with poor control)
• AKI, multi-organ dysfunction

Observation indications:

Discharge criteria (rare in true urosepsis; more applicable to uncomplicated pyelonephritis):

• NEJM[3]

Specialist consultation triggers:

• Urology: All cases with obstructive uropathy, stones, abscess, emphysematous pyelonephritis, or need for source control [27]
• Interventional radiology: PCN placement if urology unavailable or antegrade approach preferred [30]
• Infectious disease: MDR organisms, failure to improve on empiric therapy, immunocompromised host
• Critical care/ICU: Septic shock, vasopressor requirement, multi-organ dysfunction

18. Follow Up / Return Precautions

• Follow-up timing: PCP or urology within 1–2 weeks of discharge; earlier if persistent symptoms
• Repeat urine culture: Consider test of cure in complicated cases or if structural abnormality persists
• Definitive stone management: Schedule after infection clears (typically 4–6 weeks) if urolithiasis was the cause [26]
• Review culture susceptibilities and narrow/adjust oral antibiotics accordingly

Return precautions — instruct patients to return immediately for:

• Recurrent fever, rigors, or chills
• Worsening flank or abdominal pain
• Decreased urine output or inability to urinate
• Confusion, lightheadedness, or feeling faint
• Persistent vomiting or inability to take medications
• Blood in urine (new or worsening)

Expected recovery: With appropriate antibiotics and source control, clinical improvement is typically seen within 48–72 hours. Failure to improve should prompt re-imaging for undrained collection, reassessment of antibiotic coverage, and consideration of alternative diagnoses. [1][27]

References

1. Urosepsis--Etiology, Diagnosis, and Treatment. — Dreger NM, Degener S, Ahmad-Nejad P, Wöbker G, Roth S. Deutsches Arzteblatt International. 2015.

2. Urosepsis--Etiology, Diagnosis, and Treatment. — Dreger NM, Degener S, Ahmad-Nejad P, Wöbker G, Roth S. Deutsches Arzteblatt International. 2015.

3. Urosepsis--Etiology, Diagnosis, and Treatment. — Dreger NM, Degener S, Ahmad-Nejad P, Wöbker G, Roth S. Deutsches Arzteblatt International. 2015.

4. Urosepsis: Overview of the Diagnostic and Treatment Challenges. — Wagenlehner FME, Pilatz A, Weidner W, Naber KG. Microbiology Spectrum. 2015.

5. Urosepsis: Overview of the Diagnostic and Treatment Challenges. — Wagenlehner FME, Pilatz A, Weidner W, Naber KG. Microbiology Spectrum. 2015.

6. Acute Pyelonephritis in Adults. — Johnson JR, Russo TA. The New England Journal of Medicine. 2018.

7. Acute Pyelonephritis in Adults. — Johnson JR, Russo TA. The New England Journal of Medicine. 2018.

8. Clinical Situations of Bacteriology and Prognosis in Patients with Urosepsis. — Jiang Y, Li J, Zhang Y, et al. BioMed Research International. 2018.

9. Clinical Situations of Bacteriology and Prognosis in Patients with Urosepsis. — Jiang Y, Li J, Zhang Y, et al. BioMed Research International. 2018.

10. Sepsis and Septic Shock. — Meyer NJ, Prescott HC. The New England Journal of Medicine. 2024.

11. Sepsis and Septic Shock. — Meyer NJ, Prescott HC. The New England Journal of Medicine. 2024.

12. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. — Evans L, Rhodes A, Alhazzani W, et al. Critical Care Medicine. 2021.

13. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. — Evans L, Rhodes A, Alhazzani W, et al. Critical Care Medicine. 2021.

14. Severe Sepsis and Septic Shock. — Angus DC, van der Poll T. The New England Journal of Medicine. 2013.

15. Severe Sepsis and Septic Shock. — Angus DC, van der Poll T. The New England Journal of Medicine. 2013.

16. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI. — Barbara W. Trautner, Nicolás W. Cortés-Penfield, Kalpana Gupta, et al Infectious Diseases Society of America. 2025.

17. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI. — Barbara W. Trautner, Nicolás W. Cortés-Penfield, Kalpana Gupta, et al Infectious Diseases Society of America. 2025.

18. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. — Tamma PD, Aitken SL, Bonomo RA, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2023.

19. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. — Tamma PD, Aitken SL, Bonomo RA, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2023.

20. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. — Tamma PD, Heil EL, Justo JA, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

21. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. — Tamma PD, Heil EL, Justo JA, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

22. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI. — Barbara W. Trautner, Nicolás W. Cortés-Penfield, Kalpana Gupta, et al Infectious Diseases Society of America. 2025.

23. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI. — Barbara W. Trautner, Nicolás W. Cortés-Penfield, Kalpana Gupta, et al Infectious Diseases Society of America. 2025.

24. Risk Factors for Urosepsis in Chronic Kidney Disease Patients With Urinary Tract Infections. — Dimitrijevic Z, Paunovic G, Tasic D, Mitic B, Basic D. Scientific Reports. 2021.

25. Risk Factors for Urosepsis in Chronic Kidney Disease Patients With Urinary Tract Infections. — Dimitrijevic Z, Paunovic G, Tasic D, Mitic B, Basic D. Scientific Reports. 2021.

26. Pathogen Distribution and Antibiotic Sensitivity Analysis in Urosepsis Associated With Urinary Stones: A Retrospective Observational Study. — Hu Y, Wang X, Chen Y, et al. Medicine. 2025.

27. Pathogen Distribution and Antibiotic Sensitivity Analysis in Urosepsis Associated With Urinary Stones: A Retrospective Observational Study. — Hu Y, Wang X, Chen Y, et al. Medicine. 2025.

28. Urinary Tract Infections in Older Men. — Schaeffer AJ, Nicolle LE. The New England Journal of Medicine. 2016.

29. Urinary Tract Infections in Older Men. — Schaeffer AJ, Nicolle LE. The New England Journal of Medicine. 2016.

30. Urinary Tract Infections in Pregnant Individuals. — Committee on Clinical Consensus—Obstetrics Obstetrics and Gynecology. 2023.

31. Urinary Tract Infections in Pregnant Individuals. — Committee on Clinical Consensus—Obstetrics Obstetrics and Gynecology. 2023.

32. Explainable Machine Learning With Routine Biomarkers Identifies Culture-Defined Bacteremic Urosepsis. — Zhang YL, Yu DX, Zheng YY, et al. Scientific Reports. 2026.

33. Explainable Machine Learning With Routine Biomarkers Identifies Culture-Defined Bacteremic Urosepsis. — Zhang YL, Yu DX, Zheng YY, et al. Scientific Reports. 2026.

34. A Reference Standard for Urinary Tract Infection Research: A Multidisciplinary Delphi Consensus Study. — Bilsen MP, Conroy SP, Schneeberger C, et al. The Lancet. Infectious Diseases. 2024.

35. A Reference Standard for Urinary Tract Infection Research: A Multidisciplinary Delphi Consensus Study. — Bilsen MP, Conroy SP, Schneeberger C, et al. The Lancet. Infectious Diseases. 2024.

36. Early Care of Adults With Suspected Sepsis in The Emergency Department and Out-of-Hospital Environment: A Consensus-Based Task Force Report. — Yealy DM, Mohr NM, Shapiro NI, et al. Annals of Emergency Medicine. 2021.

37. Early Care of Adults With Suspected Sepsis in The Emergency Department and Out-of-Hospital Environment: A Consensus-Based Task Force Report. — Yealy DM, Mohr NM, Shapiro NI, et al. Annals of Emergency Medicine. 2021.

38. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

39. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.

40. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. — Prescott HC, Antonelli M, Alhazzani W, et al. Critical Care Medicine. 2026.

41. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. — Prescott HC, Antonelli M, Alhazzani W, et al. Critical Care Medicine. 2026.

42. Association of Electrocardiogram Abnormalities With Clinical Outcomes in Emergency Department Sepsis Patients. — Kotruchin P, Chuehongthong M, Tangpaisarn T, et al. The Western Journal of Emergency Medicine. 2026.

43. Association of Electrocardiogram Abnormalities With Clinical Outcomes in Emergency Department Sepsis Patients. — Kotruchin P, Chuehongthong M, Tangpaisarn T, et al. The Western Journal of Emergency Medicine. 2026.

44. Emphysematous Pyelonephritis With ST Elevation Accompanied by Reciprocal Changes Mimicking Acute Coronary Syndrome. — Hatakeyama K, Shono Y, Hashimoto T, et al. The American Journal of Emergency Medicine. 2023.

45. Emphysematous Pyelonephritis With ST Elevation Accompanied by Reciprocal Changes Mimicking Acute Coronary Syndrome. — Hatakeyama K, Shono Y, Hashimoto T, et al. The American Journal of Emergency Medicine. 2023.

46. ECG Changes During Septic Shock. — Rich MM, McGarvey ML, Teener JW, Frame LH. Cardiology. 2002.

47. ECG Changes During Septic Shock. — Rich MM, McGarvey ML, Teener JW, Frame LH. Cardiology. 2002.

48. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. — Sandau KE, Funk M, Auerbach A, et al. Circulation. 2017.

49. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. — Sandau KE, Funk M, Auerbach A, et al. Circulation. 2017.

50. Electrocardiographic Manifestations: Electrolyte Abnormalities. — Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. The Journal of Emergency Medicine. 2004.

51. Electrocardiographic Manifestations: Electrolyte Abnormalities. — Diercks DB, Shumaik GM, Harrigan RA, Brady WJ, Chan TC. The Journal of Emergency Medicine. 2004.

52. 2007 Guideline for the Management of Ureteral Calculi. — Preminger GM, Tiselius HG, Assimos DG, et al. The Journal of Urology. 2007.

53. 2007 Guideline for the Management of Ureteral Calculi. — Preminger GM, Tiselius HG, Assimos DG, et al. The Journal of Urology. 2007.

54. Diagnosis and Management for Urosepsis. — Wagenlehner FM, Lichtenstern C, Rolfes C, et al. International Journal of Urology : Official Journal of the Japanese Urological Association. 2013.

55. Diagnosis and Management for Urosepsis. — Wagenlehner FM, Lichtenstern C, Rolfes C, et al. International Journal of Urology : Official Journal of the Japanese Urological Association. 2013.

56. Percutaneous Nephrostomy Versus Retrograde Ureteral Stent for Acute Upper Urinary Tract Obstruction With Urosepsis. — Xu ZH, Yang YH, Zhou S, Lv JL. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. 2021.

57. Percutaneous Nephrostomy Versus Retrograde Ureteral Stent for Acute Upper Urinary Tract Obstruction With Urosepsis. — Xu ZH, Yang YH, Zhou S, Lv JL. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. 2021.

58. Choosing the Best Way for Urinary Decompression and Developing a Novel Predictive Model for Septic Shock Using SOFA in These Patients. — Law YXT, Shen L, Khor VWS, et al. International Journal of Urology : Official Journal of the Japanese Urological Association. 2022.

59. Choosing the Best Way for Urinary Decompression and Developing a Novel Predictive Model for Septic Shock Using SOFA in These Patients. — Law YXT, Shen L, Khor VWS, et al. International Journal of Urology : Official Journal of the Japanese Urological Association. 2022.

60. CIRSE Standards of Practice on Nephrostomy and Ureteric Stent Placement and Exchange. — Ryan AG, Irvine I, Bardgett H, et al. Cardiovascular and Interventional Radiology. 2026.

61. CIRSE Standards of Practice on Nephrostomy and Ureteric Stent Placement and Exchange. — Ryan AG, Irvine I, Bardgett H, et al. Cardiovascular and Interventional Radiology. 2026.